|
| Global n = 20 | BCR1 after prostatectomy n = 13 | BCR1 after radiotherapy n = 7 |
| RT2 | 5% | 7.7% | - |
| HT3 | 30% | 15.4% | 57.1% |
| RT + HT | 10% | 15.4% | - |
| SBRT4 + HT | 25% | 23.1% | 28.6% |
| RT + SBRT + HT | 20% | 30.8% | - |
| Enzalutamide + HT | 10% | 7.7% | 14.3% |